MNMD

MNMD

USD

Mind Medicine (MindMed) Inc. Common Shares

$12.000-0.100 (-0.826%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$12.100

Hoch

$12.530

Tief

$11.880

Volumen

2.12M

Unternehmensfundamentaldaten

Marktkapitalisierung

1.2B

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

1.69M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $4.7Aktuell $12.000Hoch $14.43

Ähnliche Nachrichten

BusinessWire

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the closing

Mehr anzeigen
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
BusinessWire

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing

Mehr anzeigen
Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering
BusinessWire

MindMed Announces New Employee Inducement Grant

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance

Mehr anzeigen
MindMed Announces New Employee Inducement Grant
Analyst Upgrades

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Needham starts MindMed at Buy with a $28 target, citing strong Phase 3 prospects for MM120 in anxiety and depression and solid cash position.

Mehr anzeigen
Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression